Erythropoietic protoporphyria is a severe photodermatosis that is associated with acute phototoxicity. Patients with this condition have excruciating pain and a markedly reduced quality of life. We ...

European regulators to evaluate new drug’s safety and efficacy for ‘orphan’ disease erythropoietic protoporphyria (EPP) SCENESSE®, which received an orphan drug designation for EPP in 2008, will be ...

MELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease (PD or Parkinson’s) ...

MELBOURNE, Australia and SINGAPORE, July 13, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS today revealed PRÉNUMBRA ®, the Company’s second afamelanotide product in development. PRÉNUMBRA ® is a ...

Scenesse (Clinuvel Pharmaceuticals) is a bimonthly, subcutaneous dose of afamelanotide 16mg. A New Drug Application (NDA) for the treatment of erythropoietic protoporphyria (EPP) – a rare blood ...

Clinuvel Pharmaceuticals revealed Prénumbra the company’s second afamelanotide product in development. Prénumbra is a liquid (non-solid) formulation of afamelanotide to be evaluated by Clinuvel in ...

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for afamelanotide (Scenesse, Clinuvel), the first medicine aimed at ...

Please provide your email address to receive an email when new articles are posted on . Researchers discovered that a combination of afamelanotide and NB-UV-B phototherapy resulted in statistically ...

inactivating the superoxide anion and increasing the availability of superoxide dismutase to reduce oxidative stress. Afamelanotide has a marketing authorisation in the UK under 'exceptional ...

The Department of Health has asked the National Institute for Health and Care Excellence (NICE) to produce guidance on using afamelanotide in the context of national commissioning by NHS England. The ...